AZD6244
Information
- Drug Name
- AZD6244
- Description
- Entry(CIViC)
CIViC
[No Data.]
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| AZD6244: MEK inhibitor. In two-dimensional cell cu... | MAP2K7 | MAP2K7 EXPRESSION | Sensitivity | true | MMMP | detail |
| AZD6244 is a MEK inhibitor. The mutation found in ... | MAP2K1 | MAP2K1 P124L | Resitance or Non-Reponse | true | MMMP | detail |
| AZD6244 is a MEK inhibitor | MAP2K1 | MAP2K1 I103N | Resitance or Non-Reponse | true | MMMP | detail |
| AZD6244 is a MEK inhibitor | MAP2K1 | MAP2K1 L115P | Resitance or Non-Reponse | true | MMMP | detail |
| AZD6244 is a MEK inhibitor | MAP2K1 | MAP2K1 F129L | Resitance or Non-Reponse | true | MMMP | detail |
| AZD6244 is a MEK inhibitor | MAP2K1 | MAP2K1 UNKNOWN | Resitance or Non-Reponse | true | MMMP | detail |
| AZD6244 is a MEK inhibitor | MAP2K1 | MAP2K1 Q56P | Resitance or Non-Reponse | true | MMMP | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00600496 | Active, not recruiting | Phase 1 | A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) | December 14, 2007 | December 31, 2024 |
| NCT00463814 | Active, not recruiting | Phase 1 | AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Patients With Advanced Solid Malignancies | March 8, 2007 | December 31, 2024 |
| NCT01306045 | Active, not recruiting | Phase 2 | Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies | February 8, 2011 | December 31, 2024 |
| NCT01362803 | Active, not recruiting | Phase 1/Phase 2 | AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors | September 21, 2011 | January 1, 2030 |
| NCT00710515 | Completed | Phase 1 | Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With Advanced Solid Malignancies | July 2008 | June 2010 |
| NCT00890825 | Completed | Phase 2 | AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients | April 20, 2009 | November 2, 2016 |
| NCT00936221 | Completed | Phase 2 | Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients | July 2009 | November 2014 |
| NCT00970359 | Completed | N/A | Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244 | September 2009 | April 2013 |
| NCT01021748 | Completed | Phase 1 | A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010) | November 23, 2009 | July 16, 2014 |
| NCT01116271 | Completed | Phase 2 | Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec | April 2010 | July 2012 |
| NCT01146756 | Completed | Phase 1 | MEK Inhibitor and Thoracic Radiotherapy Trial | June 4, 2010 | February 8, 2017 |
| NCT00338130 | Completed | Phase 2 | Randomised Study to Compare the Efficacy of AZD6244 vs TMZ | July 2006 | July 2013 |
| NCT00372788 | Completed | Phase 2 | AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen | August 2006 | December 2008 |
| NCT00372944 | Completed | Phase 2 | AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy | August 2006 | October 2008 |
| NCT00514761 | Completed | Phase 2 | Phase II Efficacy Study of AZD6244 in Colorectal Cancer | September 2006 | July 2008 |
| NCT01229150 | Completed | Phase 2 | Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva... | October 26, 2010 | November 21, 2015 |
| NCT01248247 | Completed | Phase 2 | BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer | June 2, 2011 | November 30, 2020 |
| NCT01287130 | Completed | Phase 1 | AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer | January 7, 2011 | August 27, 2013 |
| NCT01605916 | Completed | Phase 1 | Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer | June 2012 | May 2015 |
| NCT01160926 | Terminated | Phase 1 | Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial | July 2010 | November 4, 2016 |
| NCT01134601 | Terminated | Phase 1 | A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum | May 24, 2010 | October 22, 2012 |
| NCT00780676 | Terminated | Phase 2 | Personalized Treatment Selection for Metastatic Breast Cancer | June 2009 | May 2014 |
| NCT02583542 | Unknown status | Phase 1/Phase 2 | A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers | June 2015 | March 2020 |